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A B S T R A C T
In the current study effects of fungal extracts on the G-protein-activated inwardly rectifying potassium channel
(GIRK1/4) were screened using the automated patch-clamp method. 40 organic (n-hexane, chloroform, and 50%
methanol) and aqueous extracts were prepared from 10 mushroom species native to Hungary. Among the ex-
amined fungal fractions of different polarities some n-hexane and chloroform extracts exerted considerable ion
channel activity. One of the most active fungal species, Hypholoma lateritium was selected for further detailed
examination to determine the compounds responsible for the observed pharmacological property. Evaluation of
the ion channel activity of mushroom metabolites 1–10 revealed that lanosta-7,9(11)-diene-12β,21α-epoxy-
2α,3β,24β,25-tetraol (5) demonstrates remarkable blocking activity on GIRK current (IC50 395.1 ± 31.8 nM).
Investigation of the selectivity of the GIRK inhibitory effect proved that lanosta-7,9(11)-diene-12β,21α-epoxy-
2α,3β,24β,25-tetraol (5) has only weak inhibitory activity on hERG channel (7.9 ± 2.8% at 100 μM), exerting
more than three orders of magnitude lower blocking activity on hERG channel than on GIRK channel.
1. Introduction
Atrial fibrillation (AF) is a supraventricular tachyarrhythmia with
uncoordinated atrial activation and, accordingly, ineffective atrial
contraction. AF is the most common cardiac rhythm disturbance in
adults and the prevalence of this arrhythmia increases sharply with
advancing age. AF is potentially associated with life-threatening car-
diovascular conditions such as thromboembolism, stroke and heart
failure, consequently results in significant morbidity and mortality [1].
Even though the underlying mechanisms of AF is not yet entirely
understood, the cardiac acetylcholine-activated potassium ion channel
(IKACh) is considered a novel and attractive target for drug therapy in
the treatment of AF [2]. This ion channel is member of the G-protein-
coupled inwardly rectifying potassium channel (GIRK) superfamily and
is composed of GIRK1/4 (Kir3.1 and Kir3.4) subunits [3]. It has been
described that GIRK1/4 is constitutively active in myocytes from pa-
tients with chronic AF or from dog model of atrial tachycardia, and,
furthermore, these studies have demonstrated spontaneous openings of
these channels in myocytes from chronic AF patients [2,4,5]. Potent
selective inhibitors of GIRK, tertiapin and NIP-151 terminated AF, and
favorably prolonged the atrial effective refractory period in canine AF
model [6,7]. Taking all these findings together, constitutively active
GIRK channels in the atrium elevate proarrhythmic risk by causing
dispersion of atrial repolarization and refractoriness, therefore, a se-
lective GIRK blocker without affecting ventricular repolarization is ef-
fective and might be useful for the treatment of patients with AF.
A selective atrial target is extremely important. GIRK1 and GIRK4
subunits are abundant in atrium, but expressed in very small amounts
in ventricle [8,9]. However, many of drugs exert their arrhythmogenic
side effects through the ion channel encoded by the human ether-a-go-
go-related gene (hERG, Kv11.1), expressed in cardiac ventricular
myocytes, which has shown to be extremely promiscuous in its inter-
actions with a wide range of structurally unrelated molecules such as
psychiatric, antimicrobial, antihistamine, and even antiarrhythmic
drugs [1,10]. hERG represents the α-subunit of the ion channel re-
sponsible for rapid delayed rectifier potassium current (IKr) [11,12].
The IKr current plays a fundamental role in the phase 3 of repolarization
of the action potential; therefore, inhibition of hERG channel delays
cardiac action potential repolarization, which lengthens the action
potential duration (APD). Prolongation of ventricular action potential
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duration might be associated with an increased risk of the polymorphic
ventricular tachycardia Torsades de Pointes, which can degenerate into
ventricular fibrillation and sudden cardiac death [13–15]. In the past,
several drugs have been withdrawn from major markets because of
their proarrhythmic effect. At present, to avoid severe cardiotoxicity,
every new compound must go through preclinical safety testing de-
termined by the U. S. Food and Drug Administration, the European
Medicines Agency and other regulatory entities [16].
The popular term mushroom is applied for macrofungi with dis-
tinctive fruiting bodies observable to the naked eye. The number of
different mushroom species is estimated to be 140,000, of which only
10% are known to science. They have long been recognized for their
therapeutic values, particularly in traditional medicines of Far-Eastern
countries. Mushrooms are valuable sources of biologically active com-
pounds possessing antibacterial, anticancer and immunmodulatory
properties [17,18]. Extended investigation of active substances origi-
nated from mushrooms in different screening systems may result in
further discoveries of valuable new compounds.
In the present study, the effects of basidiomycetes mushroom ex-
tracts on the G-protein-activated inwardly rectifying potassium channel
(GIRK1/4) were investigated using the automated patch-clamp method.
For this purpose organic and aqueous extracts were prepared from 10
different mushrooms native to Hungary. The extracts of different po-
larities were investigated in the cell-based GIRK channel inhibitory
assay on HEK-GIRK cell line. One of the most active species was selected
for further detailed chemical examination to determine its biologically
active metabolites. The GIRK channel modulatory activities of the iso-
lated compounds were also evaluated, with the aim of discovering new
promising blockers of the GIRK1/4 channel. In addition, the most po-
tent blocker of GIRK proteins was further tested for its hERG-related
cardiotoxicity with automated patch-clamp technology on HEK-hERG
cell line.
Fig. 1. Blocking effects of fraction B of Hypholoma
lateritium on GIRK current. Panel A shows typical
current curves which were recorded during applica-
tion of fraction B of H. lateritium at 0.01mg/mL and
0.1mg/mL concentrations. Inset shows the applied
GIRK voltage protocol. Time course of calculated
inward currents from the −140mV segment of the
current sweeps is presented on panel B.
Table 1
Information on fungal species collected.
Family Species English name Habitat
Entolomataceae Rhodocybe popinalis (Fr.) Singer Not known Mixed woodland
Fomitopsidaceae Laetiporus sulphureus (Bull.) Murrill Chicken-of-the-woods Mixed woodland
Marasmiaceae Megacollybia platyphylla (Pers.) Kotl. & Pouzar Whitelaced shank Mixed woodland
Omphalotaceae Gymnopus dryophilus (Bull.) Murrill Russet toughshanks Mixed woodland
Gymnopus fusipes (Bull.) Gray Spindleshank Quercus sp. (parasitic)
Strophariaceae Hebeloma sacchariolens Quél. Sweet poisonpie Mixed woodland
Hypholoma fasciculare (Huds.) P. Kumm. Sulfur tuft Mixed woodland
Hypholoma lateritium (Schaeff.) P. Kumm. Brick tuft Mixed woodland
Tricholomataceae Tricholoma populinum J.E. Lange Cottonwood mushroom Populus sp. (mycorrhizal)
Tricholomopsis rutilans (Schaeff.) Singer Plums and custard Pinus sp. (saprobic)
A. Ványolós, et al. Fitoterapia 137 (2019) 104272
2
2. Materials and methods
2.1. Samples
Mushroom samples were collected in Hungary in 2012 by A.
Ványolós and members of Mushroom Society of Miskolc and of
Mushroom Society of Zemplén (Hungary). The collected species were
identified by J. Béres (Mushroom Society of Miskolc), J. Kőszeginé Tóth
(Mushroom Society of Zemplén) and A. Ványolós. Representative vou-
cher specimens (No. IC 1–10) have been deposited in the Department of
Pharmacognosy, University of Szeged. The samples were stored at
−20 °C until processing.
2.2. Sample preparation
The sporocarps of collected mushrooms were freeze-dried and
ground. Each freeze-dried sample (10 g) was extracted with 3×100mL
methanol by ultrasonication for 3×15. After filtration, the solutions
were evaporated under reduced pressure. The residues were dissolved
in 50mL of 50% aqueous MeOH and were subjected to solvent-solvent
partition between n-hexane (4×25mL) (extract A) and CHCl3
(4× 25mL) (extract B) and the residue gave extract C. After extraction
with MeOH, the residual mushroom materials were dried and extracted
with 50mL of boiling water for 15min. The filtered extracts were
freeze-dried, providing extract D.
Isolation, structure determination and characterization of com-
pounds 1–10 are described elsewhere [19].
2.3. Automated planar patch-clamp measurements
GIRK and hERG ion currents were measured using planar patch-
clamp technology in the whole-cell configuration with a four channel
medium throughput fully automated patch-clamp system (Patchliner,
Nanion Technologies GmbH, Munich, Germany; [20]. The pipetting
protocols were controlled by PatchControlHT 1.09.30 software (Nanion
Technologies GmbH., Munich, Germany). Data acquisition and online
analysis were performed with an EPC-10 Quadro patch-clamp amplifier
(HEKA Elektronik Dr. Schulze GmbH, Lambrecht/Pfalz, Germany),
using PatchMaster 2.65 software (HEKA Elektronik Dr. Schulze GmbH,
Lambrecht/Pfalz, Germany). Currents were low-pass filtered at 2.9 kHz
using the internal Bessel filter of the amplifier and digitized at 10 kHz.
Automated patch-clamp experiments were carried out at room
temperature on suspension of stable transfected cell lines. Suspension of
cells for measurements was derived from running cell culture. Cells
were maintained in incubator at 37 °C, in 5% CO2. Before experiments,
cells were washed twice with PBS (Thermo Fisher Scientific Inc.,
Waltham, USA) and then detached with trypsin-EDTA (PAN-Biotech
GmbH, Aidenbach, Germany) for 1–3min. Trypsin was blocked with
serum-containing media. The cell suspension was next centrifuged
(2min, 100 g), resuspended in serum-free media at a final density of
Table 2
Yields and blocking effects of mushroom extracts at 0.01mg/mL and 0.1mg/mL concentrations on GIRK ion channels (n=2–3).
Species Solvent Yield (w/w%) Inhibition % SEM 0.1mg/mL
0.01mg/mL 0.1 mg/mL 0.01mg/mL
Gymnopus dryophilus A 1.1 28 72 0 3
B 0.9 35 80 5 4
C 7.5 10 15 1 2
D 5.2 10 20 5 4
Gymnopus fusipes A 2.8 29 74 4 8
B 1.3 30 76 6 0
C 18.3 6 11 1 1
D 4.1 21 30 1 1
Hebeloma sacchariolens A 1.7 33 67 4 5
B 1.6 37 74 2 1
C 8.2 6 28 3 2
D 1.6 20 37 6 3
Hypholoma fasciculare A 1.6 23 53 1 4
B 3.4 25 60 6 9
C 7.2 16 35 6 3
D 4.0 12 20 4 6
Hypholoma lateritium A 2.2 33 69 3 1
B 1.0 53 79 2 1
C 16.4 25 46 0 2
D 3.9 8 14 6 3
Laetiporus sulphureus A 1.3 34 74 6 8
B 0.7 28 68 6 13
C 5.8 25 43 6 11
D 3.6 11 24 1 7
Megacollybia platyphylla A 0.9 39 61 3 15
B 0.5 29 68 6 3
C 13.0 11 11 4 6
D 6.2 8 20 0 6
Rhodocybe popinalis A 1.4 19 55 3 3
B 0.8 10 23 3 5
C 8.8 12 16 1 2
D 6.2 7 16 1 0
Tricholoma populinum A 6.0 5 25 0 4
B 1.7 41 90 2 1
C 15.0 9 17 1 16
D 4.6 17 20 3 12
Tricholomopsis rutilans A 1.3 16 52 4 3
B 2.7 37 65 4 12
C 11.5 15 31 8 11
D 1.3 12 17 0 3
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1× 106–5×106 cells/mL, and kept in the cell hotel of the Patchliner.
Cells were recovered after 15–30min and remained suitable for auto-
mated patch-clamp recordings for up to 4 h.
Stock of extra- and intracellular solutions were made for automated
patch-clamp recordings. Chemicals were purchased from Sigma-Aldrich
Corporation (St. Louis, USA). All solutions were sterile filtered. Aliquots
were stored at −20 °C and warmed up to room temperature before use.
Effects of fungal extracts and compounds isolated from Hypholoma
lateritium were tested. A stock solution of test material was prepared in
each case. The concentrations of the examined substances in the stock
solutions were 50mg of dried material/mL for the mushrooms extract
and 10mM for compounds 1–10. The solubilizing agent was dimethyl
sulphoxide (DMSO, Sigma-Aldrich Corporation, St. Louis, USA) in all
cases. Aliquots were stored at −20 °C. Before experiments, stock solu-
tions were further diluted with high K+ external solution (GIRK assay)
or external solution (hERG assay) to give appropriate concentrations for
the measurements. The final DMSO concentrations in the tested sam-
ples were 1% or less.
2.3.1. GIRK channel inhibitory assay
Experiments were carried out on HEK-293 (human embryonic
kidney) cells stably expressing the GIRK1/4 (Kir3.1/3.4) K+ channels
by adapting a method described earlier [21]. Cell line originated from
UCL Business Plc. (London, Great Britain). Cells were maintained in
DMEM (Thermo Fisher Scientific Inc., Waltham, USA) medium sup-
plemented with 10% FBS (PAN-Biotech GmbH, Aidenbach, Germany)
and 182 μg/mL zeocin (Thermo Fisher Scientific Inc., Waltham, USA).
The following solutions were used during patch-clamp recordings
(compositions in mM): external solution: NaCl 140, KCl 4, glucose-
monohydrate 5, MgCl2 1, CaCl2 3 and HEPES 10 (pH 7.4, NaOH); high
K+ external solution: NaCl 135, KCl 25, MgCl2 1, CaCl2 3 and HEPES 10
(pH 7.4, NaOH); K+-free external solution: NaCl 160, MgCl2 1, CaCl2 3
and HEPES 10 (pH 7.4, NaOH); internal solution: K-gluconate 40, NaCl
20, KF 60, EGTA 20 and HEPES 10 (pH 7.2, KOH), supplemented with
0.9 mM GTPγS before the experiments to induce channel activation.
The voltage protocol for GIRK ion channel assay (see inset on Panel
Fig. 2. Triterpenes (1−10) from Hypholoma lateritium.
Table 3
GIRK channel inhibitory activity of isolated compounds of Hypholoma lateritium
at 1 μM and 10 μM concentrations (n=2–3).
Compound inhibition % SEM
1 μM 10 μM 1 μM 10 μM
1 13 23 2 8
2 11 23 2 3
3 10 10 4 7
4 10 27 1 2
5 27 60 5 11
6 11 23 3 1
7 14 24 1 5
8 10 19 1 1
9 8 16 1 6
10 7 13 1 6
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A, Figs. 1, 3 and 4) started with a depolarizing voltage step to 60mV for
100ms before a 500ms long hyperpolarizing ramp to −140mV was
applied. Then the membrane potential remained at −140mV for
100ms before returning to the holding potential of −40mV. The in-
ward currents were calculated from the −140mV segment. The pulse
frequency was approximately 0.1 Hz.
At the beginning of recordings, the normal external solution
(4mMK+) was replaced to high K+ (25mMK+) external solution in
order to increase the current amplitude. After 2–3min of control
period, the test compounds were added to the cells in increasing con-
centrations, each for approximately 3min. Propafenone (1 μM, Sigma-
Aldrich Corporation, St. Louis, USA) was used as a reference compound.
In preliminary studies, we measured that the positive control propafe-
none exerted its effect with 373.0 ± 27.7 nM IC50 value and at 1 μM
concentration inhibited the GIRK current by 71.4 ± 4.6% (n=6).
Finally, potassium free external solution was applied to completely
cease inward potassium currents. The data were corrected with the
current values measured in the potassium free external solution, which
served as the baseline.
2.3.2. hERG channel inhibitory assay
hERG measurements were performed on HEK-293 cells stably
transfected with cDNA encoding the hERG (Kv11.1) K+ channel as
described earlier in detail [21,22]. Cell line was purchased from Cell
Culture Service (Hamburg, Germany). Cells were maintained in IMDM
(PAN-Biotech GmbH, Aidenbach, Germany) medium supplemented
with 10% FBS (PAN-Biotech GmbH, Aidenbach, Germany), 2 mM L-
glutamine (PAN-Biotech GmbH, Aidenbach, Germany), 1 mM Na-pyr-
uvate (PAN-Biotech GmbH, Aidenbach, Germany) and 500 μg/mL G418
(Thermo Fisher Scientific Inc., Waltham, USA).
The following solutions were used during patch-clamp experiments
(compositions in mM): external solution: NaCl 140, KCl 4, glucose-
monohydrate 5, MgCl2 1, CaCl2 3 and HEPES 10 (pH 7.4, NaOH); in-
ternal solution: KCl 50, NaCl 10, KF 60, EGTA 20 and HEPES 10
(pH 7.2, KOH).
The voltage protocol for hERG ion channel (see inset on Panel A,
Fig. 5) started with a short (100ms) –40mV step to establish the
baseline region. A depolarizing step was applied to the test potential of
20mV for 3 s, and then the cell was repolarized to −40mV (1 s) to
evoke outward tail current. Holding potential was −80mV. The pulse
frequency was approximately 0.1 Hz. The peak tail current was cor-
rected the leak current defined during the first period to −40mV.
Recording started in external solution. After this control period, the
test compound was applied for approximately 3min. Following the test
compound, 10 μM amitriptyline was used as a reference inhibitor then a
wash-out step terminated the pipetting protocol.
2.4. Statistics
All data are expressed as arithmetic means± standard error (SEM).
Statistical analysis was performed with Student's t-test for paired data,
and corrected using the Holm-Bonferroni method. Differences were
considered statistically significant when P value was< 0.05.
3. Results and discussion
Initially, as part of the screening study the GIRK channel inhibitory
effects of some mushroom extracts obtained from species native to
Hungary were evaluated. Extracts were examined at two concentrations
(0.01mg/mL and 0.1mg/mL) on two to three cells. Totally, 40 extracts
of 10 higher basidiomycete mushrooms (see Table 1) were assessed:
Gymnopus dryophilus, Laetiporus sulphureus, and Tricholoma populinum
Fig. 3. Blocking effects of compound 5 on GIRK
current. Panel A depicts original current sweeps
which were recorded during application of com-
pound 5 at 1 μM, 3 μM, 10 μM and 30 μM con-
centrations. Inset shows the applied GIRK voltage
protocol. Time course of calculated inward currents
from the −140mV segment of the current curves is
presented on panel B.
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are edible; Gymnopus fusipes, Hypholoma lateritium, Megacollybia platy-
phylla, Rhodocybe popinalis and Tricholomopsis rutilans are either not
recommended for consumption or there are conflicting reports on their
edibility; while Hebeloma sacchariolens and Hypholoma fasciculare are
poisonous species. To the extent of our knowledge no other study has
previously investigated the potential GIRK channel activity of mush-
rooms. According to the results obtained some fungal species display
notable inhibitory activity on GIRK channel. G. dryophilus and G. fusipes
are related mushrooms, which have not been extensively studied, the
former contains a water-soluble polysaccharide, which has a potential
immunomodulatory property based on the inhibition of NO production
[23,24]; the latter is a parasitic, root-decay fungus, which has been
recently identified as a source of unique cyclic octadecapeptides. [25].
Very little is known about the chemistry of H. sacchariolens, a small
mushroom with a bitter taste, but a sweet and flowery smell. According
to Wood et al., the source of the specific, pleasant odor is 2-amino-
benzaldehyde [26]. H. lateritium, brick cap by its vernacular name, is a
fairly popular edible mushroom in Japan, Korea and the United States,
but in Europe it is considered inedible. Compared to its more common
relative, the poisonous sulfur tuft (H. fasciculare), the chemistry and
Fig. 4. Inhibitory effects of compound 5 on GIRK current. Panel A displays representative current curves which were recorded during application of compound 5 at
0.1 μM, 0.3 μM, 1 μM and 3 μM concentrations. Inset shows the applied GIRK voltage protocol. Time course of calculated inward currents from the −140mV segment
of the current curves is presented on panel B. Panel C shows the dose-response curves of compound 5. The GIRK channel inhibitory activity of compound 5 could be
characterized by the relative IC50 value of 395.1 ± 31.8 nM (n=5).
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pharmacology of H. lateritium are explored in a weaker extent. This
species was found to produce several triterpenes e.g. fasciculols, fasci-
culic acids and sublateriols as well as sesquiterpenes eg. naematolin, a
caryophyllane derivative with cytotoxic activity [27–29].
L. sulphureus, commonly known as sulphure polypore, is a delicious
bracket fungus, growing on dead or living trees. It has a vast scientific
literature, many of its chemical constituents (polysaccharides, tri-
terpenes, polyene pigments) have been described [30–32], possessing a
variety of pharmacological properties (anticancer, antimicrobial, anti-
oxidant and hypoglycemic) [31,33,34]. T. populinum - also known as
cottonwood mushroom - is a mycorrhizal fungus with lower culinary
value which produces ergostane type steroids and methylsulfinylade-
nosine derivatives [35].
Among the fractions with different polarities, fraction A (n-hexane
fractions with the more lipophilic constituents) and fraction B (CHCl3-
soluble compounds) proved to be active (i. e., at least 50% decrease in
the current at 0.1 mg/mL concentration). The aqueous (fraction D) and
aqueous MeOH (fraction C) extracts did not demonstrate considerable
activity on GIRK channel (< 40% decrease in the current at 0.1 mg/mL)
(see Table 2.)
However, there are some exceptions: neither fraction B of R. popi-
nalis nor fraction A of T. populinum exerted remarkable blocking effect
on the GIRK channel, whereas fractions C of L. sulphureus and H. la-
teritium proved to have notable inhibitory activities.
Fraction B of H. lateritium proved to be the most effective (53%
decrease on GIRK current) at the lower (0.01mg/mL) concentration
among the tested fungal extracts (Fig. 1).
Therefore, this species was chosen for in-depth chemical analysis in
order to identify the secondary metabolites responsible for the observed
ion channel activity. Thanks to combined chromatographic techniques
we have previously identified a series of triterpenes (see Fig. 2):
fasciculic acid B (1), fasciculol E (2), fasciculol C (3), fasciculol F (4),
lanosta-7,9(11)-diene-12β,21α-epoxy-2α,3β,24β,25-tetraol (5), de-
methylincisterol A2 (6), and 3β-O-glucopyranosyl-5,8-epidioxyergosta-
6,22-diene (7), ergosterol (8), 3β-hydroxyergosta-7,22-diene (9), and
cerevisterol (10) [19].
The fungal metabolites were involved in the GIRK channel in-
hibitory assay at 1 μM and 10 μM concentrations. Compounds were
tested on two to three cells (Table 3).
Most of the isolated metabolites possessed moderate activity on
GIRK channel except compound 5, which found to be an active in-
hibitor of GIRK channel. Therefore, the dose-response curve and IC50
value of 5 were characterized in detailed experiments where its effect
was tested in 4 concentrations on 5 cells. Initially, investigations were
performed at 1 μM, 3 μM, 10 μM and 30 μM concentrations. GIRK cur-
rent was considerably reduced by these concentrations; the effects on
the inward current were statistically significant in all tested con-
centrations. Application of compound 5 at 1 μM concentration inhibited
the GIRK current by 42.0 ± 6.4%. Elevation of the concentration of 5
to 3 μM and to 10 μM resulted in further decrease in GIRK current
(60.8 ± 5.0% and 66.4 ± 4.5% inhibitions, respectively). Further
increase in test compound level did not alter the current (66.7 ± 4.6%
inhibition at 30 μM). Consequently, the maximum effect was de-
termined to this value, and, presumably, the drug may only inhibit
66.7% of the current even at the highest doses (Emax= 0.6675).
Original GIRK current curves and the time course of decrease in the
current are shown on Fig. 3. Compound 5 was also tested in detailed
experiments on GIRK cell line at 0.1 μM, 0.3 μM, 1 μM and 3 μM con-
centrations, in order to acquire the complete dose-response curve. GIRK
current was considerably reduced by compound 5 in concentration-
dependent manner. The relative IC50 value (the concentration corre-
sponding to a response midway between the estimates of the lower and
Fig. 5. Effects of compound 5 on hERG current.
Panel A presents typical hERG current sweeps during
the application of 100 μM compound 5. The inset
shows the applied hERG voltage protocol. The ori-
ginal current traces reveal that 5 slightly blocked the
hERG channel, while addition of reference com-
pound amitriptyline (10 μM) fully blocked the cur-
rent. Time course of decrease in the peak tail current
are presented on panel B.
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upper plateaus of the dose-response curve, i.e., 0% and 66.7% inhibi-
tion) was determined to be 395.1 ± 31.8 nM (Fig. 4) [36].
Compound 5 was also tested on HEK-hERG cell line and selectivity
of their GIRK blocking effect was evaluated with these experiments.
Selectivity study was performed at 100 μM concentration on 12 cells.
Compound 5 exhibited only slight inhibitory activity (7.9 ± 2.8%) on
hERG channel even at this high concentration, showing more than three
orders of magnitude higher blocking activity on GIRK channel com-
pared to the results obtained on hERG channel. Original hERG current
sweeps during the application of compound 5 at 100 μM concentration
and the time course of decrease in the peak tail current are shown on
Fig. 5.
Atrial fibrillation (AF) is the most common serious abnormal heart
rhythm. In the last two decades, AF has become a very important public
health issue, and responsible for huge and rapidly growing healthcare
expenditures in Western countries [1,37]. AF is present in
0.12%–0.16% of those younger than 49 years, in 3.7%–4.2% of those
aged 60–70 years, and in 10%–17% of those aged 80 years or older
[37].> 750,000 hospitalizations happen because of AF, and it con-
tributes to an estimated 130,000 deaths each year just in the U.S. [38].
Current antiarrhythmic drugs have numerous disadvantages, particu-
larly the lack of atrial selectivity associated with an increased risk of
side effects especially proarrhythmia and the poor efficacy rate (e.g.,
50–60% for amiodarone, which is generally considered as the most
effective drug). With this background, more targeted approaches are
required to improve therapy of AF [1,39].
Exploiting the potential biological activity of macrofungi, extracts of
basidiomycete mushrooms were investigated in our GIRK screen
system, with the aim to identify natural sources of promising ion
channel blocking compounds. Extracts of different polarity were
screened, and one of the most active species, H. lateritium was further
investigated for active compounds. Among fungal metabolites 1–10,
compound 5 demonstrated notable blocking activity on GIRK current.
Considering its intense blocking effect and high selectivity, 5 is a po-
tential promising agent in treatment of AF, despite no complete in-
hibition was observed. The current study unambiguously confirms that
higher macrofungi deserve special attention in terms of secondary
metabolites with valuable pharmacological properties.
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